| Literature DB >> 15705318 |
Aharon Abbo1, Shiri Navon-Venezia, Orly Hammer-Muntz, Tami Krichali, Yardena Siegman-Igra, Yehuda Carmeli.
Abstract
To understand the epidemiology of multidrug-resistant (MDR) Acinetobacter baumannii and define individual risk factors for multidrug resistance, we used epidemiologic methods, performed organism typing by pulsed-field gel electrophoresis (PFGE), and conducted a matched case-control retrospective study. We investigated 118 patients, on 27 wards in Israel, in whom MDR A. baumannii was isolated from clinical cultures. Each case-patient had a control without MDR A. baumannii and was matched for hospital length of stay, ward, and calendar time. The epidemiologic investigation found small clusters of up to 6 patients each with no common identified source. Ten different PFGE clones were found, of which 2 dominated. The PFGE pattern differed within temporospatial clusters, and antimicrobial drug susceptibility patterns varied within and between clones. Multivariate analysis identified the following significant risk factors: male sex, cardiovascular disease, having undergone mechanical ventilation, and having been treated with antimicrobial drugs (particularly metronidazole). Penicillins were protective. The complex epidemiology may explain why the emergence of MDR A. baumannii is difficult to control.Entities:
Mesh:
Year: 2005 PMID: 15705318 PMCID: PMC3294361 DOI: 10.3201/eid1101.040001
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Figure 1Distribution of case-patients according to ward.
Figure 2Monthly case distribution
Figure 3A typical pulsed-field gel electrophoresis analysis of selected isolates of A. baumannii restricted with ApaI. Lane 1 shows λ ladder used as molecular size marker. Lanes 11–13 are of strains not included in the trial. The gel shows 6 different clones of A. baumannii: 5 isolates belong to clone A and that 2 belong to clone B (the two dominant clones). Single isolates belonging to clones C, D, E, and F can be seen.
Characteristics of 51 strains available for PFGE typing, 2001*
| Clone | No. of isolates | No. of wards | Months | Carbapenem resistance | Sulbactam resistance |
|---|---|---|---|---|---|
| A | 22 | 14 | January–June | 16 | 1 |
| B | 10 | 8 | February–July | 1 | |
| C | 4 | 4 | January–June | 1 | 2 |
| D | 2 | 2 | January, June | ||
| E | 2 | 1 | January | ||
| F | 3 | 3 | March, April | ||
| I | 5 | 4 | February–April | 2 | |
| Lone† | 1 | 1 | January | ||
| Lone† | 1 | 1 | January | ||
| Lone† | 1 | 1 | April |
*PFGE, pulsed-field gel electrophoresis. †Lone, unique clone; each had a different ward of isolation.
Group comparison: patients’ characterization and possible risk factors for Acinetobacter baumannii isolation*†
| Cases, n (%) | Controls, n (%) | OR | 95% CI | p value | |
|---|---|---|---|---|---|
| Demographic parameters | |||||
| Average age, y (SD) | 67.7 (16.42) | 64.4 (19.15) | 1.012 | 0.996–1.03 | 0.134 |
| Female | 47 (40) | 59 (50) | |||
| Male | 71 (60) | 59 (50) | 1.48 | 0.89–2.45 | 0.13 |
| Smoking | 35 (30) | 43 (36) | 0.72 | 0.41–1.27 | 0.26 |
| Alcohol usage | 7 (6) | 5 (4) | 1.5 | 0.42–5.31 | 0.53 |
| Admission from home | 23 (20) | 12 (10) | 2.12 | 0.96–4.76 | 0.065 |
| Concomitant diseases | |||||
| Ischemic heart disease | 82 (69) | 61 (52) | 2.33 | 1.27–4.27 | 0.006 |
| Lung disease | 59 (50) | 50 (42) | 1.578 | 0.82–2.72 | 0.183 |
| Diabetes | 39 (33) | 28 (24) | 1.578 | 0.88-2.8 | 0.119 |
| Liver disease | 10 (8) | 18 (15) | 0.555 | 0.25–1.2 | 0.136 |
| Kidney disease | 35 (30) | 27 (23) | 1.388 | 0.76–2.54 | 0.288 |
| Posttransplantation | 7 (6) | 3 (3) | 2.333 | 0.6–9.02 | 0.22 |
| Malignancy | 35 (30) | 38 (32) | 0.923 | 0.53–1.6 | 0.777 |
| Clinical parameters | |||||
| Unconsciousness | 40 (43) | 26 (22) | 0.706 | 0.48–1.02 | 0.069 |
| Bedridden | 88 (75) | 79 (76) | 1.45 | 0.82–2.56 | 0.201 |
| In-house dialysis | 11 (9) | 4 (3) | 2.5 | 0.78–7.97 | 0.121 |
| Mechanical ventilation | 70 (59) | 47 (40) | 2.916 | 1.51–5.61 | 0.001 |
| Admission in last 3 months | 56 (47) | 52 (44) | 1.148 | 0.68–1.92 | 0.6 |
| ICU stay | 34 (92) | 35 (30) | 0.984 | 0.94–1.02 | 0.473 |
| Immunosuppression treatment | 29 (25) | 27 (32) | 1.095 | 0.9–1.97 | 0.763 |
| Major surgery | 33 (28) | 33 (28) | 1 | 0.51–1.95 | 1 |
| Isolation of susceptible | 6 (5) | 6 (5) | 1 | 1 | |
| Antimicrobial treatment | |||||
| Home antimicrobial treatment | 16 (41) | 6 (5) | 2.666 | 1.04–6.81 | 0.04 |
| In-house antimicrobial treatment | 104 (88) | 96 (81) | 1.727 | 0.82–3.63 | 0.149 |
| Average number of antimicrobial agents (SD) | 3.025 (2) | 2.97 (2) | 1.015 | 1 | 0.847 |
| Penicillin administration‡ | 42 (63) | 54 (46) | 0.647 | 0.37–1.1 | 0.112 |
| Cephalosporin use (1st, 2nd generation) | 31 (26) | 34 (92) | 0.9 | 0.476–1.701 | 0.746 |
| 3rd generation cephalosporin use | 53 (54) | 42 (63) | 1.631 | 0.92–2.88 | 0.093 |
| 4th-generation cephalosporin use | 17 (41) | 17 (14) | 1 | 0.49–2.04 | 1 |
| Macrolides | 21 (18) | 11 (9) | 2.25 | 0.97–5.17 | 0.056 |
| Metronidazole | 48 (14) | 35 (30) | 1.933 | 1.03–3.6 | 0.038 |
| Gentamicin | 23 (19) | 27 (32) | 0.777 | 0.38–1.56 | 0.481 |
| Amikacin | 12 (10) | 19 (16) | 0.5 | 0.2–1.24 | 0.134 |
| Clindamycin | 7 (6) | 8 (7) | 0.875 | 0.32–2.41 | 0.796 |
| Vancomycin | 22 (19) | 22 (19) | 0.944 | 0.48–1.83 | 0.866 |
| Carbapenem | 10 (8.47) | 10 (8.47) | 0.875 | 0.32–2.41 | 0.796 |
| Invasive procedures | |||||
| Central line | 69 (58) | 70 (59) | 0.958 | 0.54–1.7 | 0.884 |
| Arterial line | 35 (30) | 34 (29) | 0.933 | 0.45–1.93 | 0.85 |
| Foley catheter | 96 (81) | 76 (64) | 2.42 | 1.3–4.52 | 0.005 |
| Other bedside procedures§ | 63 (53) | 78 (67) | 0.531 | 0.29–0.95 | 0.035 |
*OR, odds ratio; CI, confidence interval; SD, standard deviation; ICU, intensive care unit. †All variables were recorded up to the time of inclusion in the study. ‡Including semisynthetic penicillin and β-lactamase‑containing products. §Including tracheostomy, bedside débridement, chest tube insertion, and gastrointestinal endoscopy.
Multivariate analysis for risk factors for Acinetobacter baumannii*†
| Parameter‡ | OR | 95% CI | p value |
|---|---|---|---|
| Male sex | 3.84 | 1.63–8.99 | 0.002 |
| Ischemic heart disease | 3.35 | 1.44–7.77 | 0.005 |
| Mechanical ventilation | 6.27 | 2.27–17.33 | <0.001 |
| Penicillin use§ | 0.38 | 0.16–0.90 | 0.029 |
| Metronidazole use | 2.33 | 0.98–5.83 | 0.071 |
| Any home antimicrobial drug treatment | 4.74 | 1.31–17.15 | 0.018 |
*OR, odds ratio; CI, confidence interval. †Adjusted for length of hospital stay prior to entry to the study. ‡All parameters had been present before A. baumannii identification. §Including semisynthetics with or without a β-lactamase inhibitor (never sulbactam).